Endpoints News 8 dic 2025 #ASH25: Will a biotech’s pivot away from obesity let it compete with Novartis in leukemia?
BioPharma Dive 8 dic 2025 Terns drug shows potential to challenge Novartis’ blockbuster leukemia treatment
BioPharma Dive 26 nov 2025 Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3